Efficacy of Ibrexafungerp (formerly SCY-078) Against Pneumocystis Pneumonia in a Murine Therapeutic Model

Preclinical Safety Evaluation of the Novel Antifungal Ibrexafungerp (formerly SCY-078) Supports Long-Term Dosing

Penetration of Ibrexafungerp (formerly SCY-078) versus Micafungin at the Site of Infection in an Intra-abdominal Candidiasis Mouse Model

Activity of a novel 1,3-beta-D-glucan inhibitor, Ibrexafungerp (formerly SCY-078), against Candida glabrata

Efficacy of Oral Ibrexafungerp (IBX, Formerly SCY-078) in the Treatment of Candida auris Infection in a Murine Disseminated Model

Interim Analysis of a Phase 3 Open-label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (formerly SCY-078) in Patients with Refractory or Intolerant Fungal Diseases (FURI)

Ibrexafungerp, a Novel Oral Antifungal, Demonstrates No Reproductive or Developmental Harm in Preclinical Models

A Phase 2b, Dose-Finding Study Evaluating Oral Ibrexafungerp in Vulvovaginal Candidiasis (DOVE)

In Vitro Activity of the Novel Agent, Ibrexafungerp (formerly SCY-078) Against Candida spp. (Including Fluconazole- Resistant Isolates) Being Developed for the Treatment of Vulvovaginal Candidiasis

Oral Ibrexafungerp (SCY-078) in Refractory Fungal Diseases
^{Interim Analysis by Pathogen of a Phase 3 Open-label Study (FURI)}

Oliver A. Cornely MD, FECMM, FIDSA, FAAM, FACP
Consultant, Infectious Diseases
Director, European Mycology Excellence Center
University Hospital of Cologne
ECCMID 2019
April 2019